11th Annual Meeting of the Society of Urologic Oncology

Extraordinary Opportunities for Discovery
December 8 – 9, 2010
Bethesda North Marriott Hotel & Conference Center

December 10 at the
Natcher Conference Center, National Institutes of Health

Bethesda, Maryland

*Register before November 15, 2010 to receive discounted pricing!

Click here to Register online Now!

Conference Location

• Thursday, December 9, 2010 – All functions held at Marriott Bethesda North
• Friday, December 10, 2010 – Industry sponsored breakfasts will be held at Marriott Bethesda North and scientific sessions will be held at Natcher Conference Center.

President’s Message

Friends and Colleagues:

It is a pleasure to invite you to attend the 11th Annual Meeting of the Society of Urologic Oncology, “Extraordinary Opportunities for Discovery”, taking place December 8th – 10th in Bethesda, Maryland. Wednesday and Thursday sessions will be held at the Bethesda North Marriott Hotel & Conference Center, while Friday’s sessions will be at the NIH’s Natcher Conference Center.

The Program Committee, chaired by Drs. Seth Lerner and Adam Kibel, has done an exceptional job putting together a stimulating and comprehensive program. This year’s meeting will incorporate a good mix of informative presentations, interesting case studies, rousing debates and lively panel discussions with time for questions and answers. Sessions will be broken out into four areas of study: bladder, prostate, testis and kidney cancer. And for the first time, the SUO Clinical Trials Consortium will be presenting a scientific session which will include prostate, bladder and renal organ site presentations. As in the past, the program will include a special session for the Y.U.O. lead this year by Dr. Yair Lotan.

I hope that each of you will consider attending this important annual meeting. The topics covered are timely and impact many areas of
urologic oncology. I look forward to seeing all of you in Bethesda this December.

Eric A. Klein, MD
SUO President, 2010 – 2011

SOCIETY OF UROLOGIC ONCOLOGY
PROPOSED BYLAWS CHANGES
2010

A. Fellowship Committee: This committee shall be responsible for establishing the program requirements for SUO-accredited urologic oncology fellowships and for reviewing all applications for certification and re-certification. They will arrange site visits of all programs, determine certification status, and notify program directors of the committee decisions. They will also issue certificates of completion to all graduating fellows completing a SUO-certified fellowship program. The Chair of the committee shall be appointed by the President for a term of 3 years. The slate of potential candidates will be submitted by the fellowship committee to the President to assist with selection. There will be up to 4 (5) five additional members appointed by the Chair with the approval of the President, each serving 3 years, with a new member appointed each year to replace an outgoing member. The outgoing Chair will serve as a committee member for one additional year after being replaced, to ensure continuity. Meetings of the committee will be determined by the Chair, The Chair shall report at the Annual Meeting.

Approval of the new SUO accredited fellowship programs will be the ultimate responsibility of the Executive Board, after consideration of the recommendations of the Fellowship Committee. The Fellowship Committee will be charged with establishing the requirements for the SUO Fellowships and for approval and reaccreditation of all SUO Fellowship Programs. Programs will be approved on a biannual basis at the SUO Winter Meeting and the AUA meeting.

General Information

The 11 th Annual Scientific Meeting in urologic oncology will be held December 8 – 10, 2010 at the Marriott Bethesda North Hotel & Conference Center and the Natcher Conference Center on the campus of the National Institutes of Health. The Society of Urologic Oncology and the National Cancer Institute’s Urologic Oncology Program will jointly sponsor this interactive meeting where all attendees participate in the discussions. State-of-the-art topics on prostate, kidney and bladder cancer, as well as, strategies in urologic oncology will be discussed.

Who Should Attend?

• Urological Surgeons
• Medical Oncologists
• Radiation Oncologists
• Research Scientists
• Residents / Fellows-in-Training

Locations

Wednesday and Thursday, December 8 – 9, 2010 – All functions
will be held at Bethesda North Marriott Hotel & Conference Center
Friday, December 10, 2010 – Industry sponsored breakfasts will
be held at Bethesda North Marriott and scientific sessions will be
held at Natcher Conference Center.

Attendee Participation

This meeting is designed to be a discussion of issues among members of the urologic oncology community at the National Institutes of Health. All attendees participate in the discussions and, depending on the session, may present up to two slides.

Meeting & Poster Sessions

The SUO Annual Meeting Scientific session will be held at the Bethesda North Marriott Hotel & Conference Center and the Natcher Conference Center, National Institutes of Health (NIH), in Bethesda, Maryland. The city’s Metro Red Line easily connects the Bethesda North Marriott to the NIH. Please allow additional time to clear security when entering the NIH for the meeting.

Registration/Information Desk Hours
Wednesday, December 8th: 2:00 p.m. – 6:00 p.m. (Marriott)
Thursday, December 9th: 6:30 a.m. – 5:00 p.m. (Marriott)
Friday, December 10th: 7:00 a.m.– 5:00 p.m. (Natcher Center)

Exhibit Hall Hours
Thursday, December 9th: 6:30 a.m. – 2:00 p.m.
SUO Welcome Reception: 6:30 p.m. – 7:30 p.m.

2010 Young Urologic Oncologists (YUO) Program
Moderator: Yair Lotan, MD; The University of Texas Southwestern Medical Center
Friday, December 10, 2010
8:00 a.m. – 8:30 a.m.  
Location: Auditorium

Young Urologic Oncologist Dinner
Wednesday, December 8, 2010
6:00 p.m. - 10:00 p.m.
Location: Grand Ballroom, Salon H

Membership in the YUO Section of the Society of Urologic Oncology consists of fellows, scientists, and board certified or eligible physicians who are members of the SUO and have some post-residency training in urologic oncology. Membership is limited to the first seven years after completion of fellowship.

HOTEL INFORMATION

The SUO 2010 Winter Meeting will be held at the Marriott Bethesda North Hotel and Natcher Center at the National Institutes of Health in Bethesda, MD. Special room rates have been arranged for meeting attendees at the Marriott.

Bethesda North Marriott Hotel & Conference Center
5701 Marinelli Road
Bethesda, Maryland 20852
Phone: (301) 822-9200
Fax: (301) 822-9201
Room Rate: $149.00
Hotel Deadline (Cut-Off Date): November 15, 2010

Reservations:
Individuals can make reservations by calling the Bethesda North Marriott reservations department at (800) 228-9290 or (301) 822-9200. All reservations must be accompanied by a first night room deposit or guaranteed with a major credit card. The SUO encourages you to make your reservation early, as the hotel may sell out before the cut-off date. After that date, reservations will be accepted on a space-available basis and higher rates may apply.

SUO-CTC Board Meeting
Marriott Bethesda North
Bethesda, Maryland
Wednesday, December 8, 2010
3:00 p.m. – 6:00 p.m. (Tentative)

SUO Board of Directors Meeting
Marriott Bethesda North
Bethesda, Maryland
Wednesday, December 8, 2010
6:00pm – 9:00pm

Conference Location
Thursday, December 9, 2010 – All functions will be held at Bethesda North Marriott Hotel & Conference Center.
Friday, December 10, 2010 – Industry Sponsored breakfasts will be held at Bethesda North Marriott Hotel & Conference Center,
and Scientific Sessions will be held at Natcher Conference Center.

Natcher Conference Center, National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland

TRAVEL & TRANSPORTATION

Car

TO NATIONAL INSTITUTES OF HEALTH (FROM BETHESDA NORTH MARRIOTT) Head northeast on Marinelli Rd toward Rockville Pike. Take the first right onto MD-355 S/Rockville Pike. Destination will be on the right.

Train

Metro Transit is the transit system for Bethesda and the Washington, DC area. For more information, go to www.wmata.com . The Marriott Bethesda North is located 0.3 miles west of the White Flint stop (Red Line) of the Metro Transit. Take the Red Line two stops to Medical Center. The Natcher Center is located directly behind this stop. Natcher Conference Center is in building #45 and all visitors have to go to the Gateway Center and park there. Parking is $12.00 per day and is less than a block away from building 45.

The Red Line also provides easy access to the free monuments and museums in Washington, DC, along with the Natcher Conference Center at the National Institutes of Health.

For more information on parking and driving to NIH, please visit: http://www.nih.gov/about/visitor/index.htm

ADDITIONAL REGISTRATION INFORMATION

Early Registration Deadline

November 15, 2010 is the deadline for receipt of the SUO Winter Meeting Pre-Registration Form. All registration forms received at the SUO office after November 15, 2010 will be considered late and will be charged a $100.00 late fee. All on-site meeting registrations will also be assessed at the late fee.

Refunds/Cancellations

Requests for registration cancellations/refunds must be submitted in writing to the SUO Executive Office by November 29, 2010. All refund requests will be subject to a $100.00 processing fee. No refunds will be made after November 29, 2010.

Pre-Registrants

SUO pre-registrants will receive a complete registration packet on-site at the registration/information desk. The packet will include badges, social tickets, and general meeting information.

Special Needs

For accommodations on the basis of disability or special dietary needs, please call (847) 264-5901.

Meals

A continental breakfast, lunch and mid-morning snack on both days of the meeting are included in the registration fee.

Young Urologic Oncologist Dinner
Wednesday, December 8, 2010
Time: 6:00 p.m. - 9:30 p.m.
Location: Grand Ballroom, Salon H
Attire: Business Casual

Membership in the YUO Section of the Society of Urologic Oncology consists of fellows, scientists, and board certified or eligible physicians who are members of the SUO and have some post-residency training in urologic oncology. Membership is limited to the first 7 years after completion of fellowship.

SUO Dinner at the Marriott Bethesda North
Thursday, December 9, 2010
Time: 7:00 p.m. – 10:00 p.m.
Location: Grand Ballroom, Salons A&B
Attire: Business casual attire is appropriate

Enjoy dinner with friends and colleagues at the Marriott Bethesda North. Registration for this is an additional cost of $70.00 per person ($40.00 for fellows, nurses and residents).

The Executive Office of the SUO manages registration for the SUO Winter Meeting. Please call the SUO office at (847) 264-5901 if you have any questions.

Educational Needs & Objectives

Needs

There is a need to increase communication among urologic oncology researchers and forge a strong relationship between the National Cancer Institute and the Society of Urologic Oncology, as well as the Society’s members and others interested in Bladder, Prostate, Kidney and Testis Cancers. This relationship will provide a community of urologic oncologists with the most up-to-date research that will provide optimal patient care.

Bladder cancer is the second most common genitourinary cancer in males and the fourth most common in females. There will be an
estimated 71,000 new cases and 15,000 deaths from bladder cancer in 2010.1 Approximately 70% of the time, patients present with nonmuscle invasive disease. Of those, 70% are Ta lesions, 20% T1, and 10% carcinoma in situ (CIS).2 Muscle invasive cancer accounts for the remainder of patients and 80% of these patients present de novo with invasive cancer as their first manifestation of the disease. Level I evidence supports the integration of systemic chemotherapy with radical cystectomy and most studies support the use of neoadjuvant cisplatin based multi-agent regimens. Despite these data less than 20% patients receive peri-operative chemotherapy.

Radical cystectomy is considered the standard of care for treatment of muscle invasive urothelial cancer in patients who are medically fit and accepting of surgery. There are several non-cystectomy surgical options for patients motivated to pursue bladder sparing or are not medically fit for cystectomy. These include partial cystectomy, radical transurethral resection and radiation therapy with or without integration of cystectomy chemotherapy. Understanding the inclusion criteria and outcomes for these various non-cystectomy options is critical for optimizing cancer control and long-term preservation of quality of life.

Randomized data has demonstrated that cytoreductive nephrectomy followed by immunotherapy provides a survival advantage over immunotherapy alone. With the introduction of targeted therapy such as mTOR inhibitors and Tyrosine Kinase Inhibitors, the treatment algorithm is under evolution. Urologists and medical oncologists manage these patients together and as such, an understanding of the role of cytoreductive nephrectomy in metastatic disease is needed to best treat patients.

Renal preservation using partial nephrectomy has gained acceptance over the past decade and now is the treatment of choice for small peripheral lesions (<4cm) and its role is expanding for lesions between 4 and 7 cm. The question has been raised as to the management of large renal masses (>7cm). Elective partial nephrectomy will preserve renal function but at the potential cost of increased risk of tumor recurrence. An understanding of the costs and benefits of elective partial nephrectomy for larger renal masses is critical to the management of these patients. A second trend in renal urologic oncology is the increased utilization of robotic and laparoscopic partial nephrectomy. This clearly provides tumor control with decreased pain. A cost is the difficulty utilizing renal cooling when using a minimally invasive approach. Since renal cooling preserves renal function, there are concerns that renal function maybe altered. Clinicians need to understand the biology and clinical implications of warm ischemia, to allow proper selection of patients and techniques for treatment of renal masses.

Prostate cancer is the most common non-cutaneous cancer in men in the US, and the second leading cause of male cancer mortality. Intense research has focused on the low risk patient (who is likely being over treated) and the high-risk patient (who is likely being undertreated). However, the majority of patients treated today have intermediate risk disease. Patients and physicians continue to struggle with the optimal management of these patients. An understanding of the advantages and disadvantages of specific treatments allows optimal counseling of this patient population.

The management of patients with adverse pathology is also difficult. While randomized trials have demonstrated improved outcomes with adjuvant external beam radiation therapy, this modality has not been widely accepted. This is in large part because the trials were run prior to the introduction of PSA testing. Many believe that close monitoring with early salvage therapy is as good as primary adjuvant radiation therapy. An understanding of the advantages and disadvantages of each approach is important to properly advise patients following treatment. In addition, novel markers are on the horizon, which may allow improved identification of patients truly in need of additional therapy. Utilization of these markers in the future will allow better risk stratification of this patient population.

Lastly, until recently, effective systemic agents following androgen deprivation for prostate cancer was limited to docetaxel. However, in the past year, two new agents received FDA approval and additional agents with great promise are being evaluated. Clearly more effective treatment is an improvement in patient care; however the sequencing of agents has not been defined. An overview of the novel agents and when they should optimally be used will help clinicians manage patients with advanced prostate cancer.

Germ cell tumors of the testicle are the most common solid tumor malignancies in young healthy men. Non-seminoma presents with metastatic disease in 70 % of patients and the cure rate with cisplatin based chemotherapy is dependent on the extent and sites of disease and serum tumor marker elevation. Management of residual masses after chemotherapy is controversial and is dependent on location – retroperitoneal and extraperitoneal – and size. When to operate, the extent of surgery, and when to observe can be one of the most challenging decisions in urologic oncology.

Objectives
Following participation in this program, attendees should be able to:

• Employ a state of science look at the evidence supporting peri-operative chemotherapy as part of a multimodality treatment for invasive bladder cancer
• Identify non-radical cystectomy options for managing muscle invasive bladder cancer with a focus on the proper selection of patients for the various treatment modalities
• Describe the mechanisms of injury caused by renal ischemia
• Assess the risk and benefits of partial nephrectomy for the large renal mass.
• Assess the role of cytoreductive nephrectomy in the targeted therapy era.
• Report recent advances in systemic therapy for advanced prostate carcinoma
• Identify new biomarkers assessing risk in patients with locally advanced prostate carcinoma.
• Describe optimal treatment strategies for prostate cancer patients with intermediate risk disease.
• Illustrate an algorithm for managing small residual masses after chemotherapy for metastatic germ cell testicular
  tumors

Evaluation of Quality of Activity
The educational quality of the meeting will be assessed with evaluation questionnaires to be filled out by the participants.

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation
Council for Continuing Medical Education through the joint sponsorship of the University of Oklahoma College of
Medicine and the Society of Urologic Oncology. The University of Oklahoma College of Medicine is accredited by the
ACCME to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this educational activity for a maximum of 11.00 AMA
PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the
activity.

Conflict Resolution Statement
The University of Oklahoma College of Medicine, Office of Continuing Medical Education has reviewed this activity’s speaker and planner disclosures and resolved all identified conflicts of interest, if applicable.

General Disclaimer of the Society of Urologic Oncology, Inc.
The statements and opinions contained in this program are solely those of the individual authors and contributors and not of the Society of Urologic Oncology, Inc. The appearance of the advertisements is not a warranty, endorsement or approval of the products or services advertised or of their effectiveness, quality or safety. The content of this publication may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses. The Society of Urologic Oncology, Inc., disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the abstracts or advertisements.

Special Assistance
We encourage participation by all individuals. If you have a disability, advance notification of any special needs will help us better serve you. Call (847) 264-5901 if you require special assistance to fully participate in the meeting.

Thank You to Our 2010 Industry Partners, Grant Supporters & Exhibitors

Industry Partners
Amgen
Dendreon
GE Healthcare

Grant Supporters
Centocor Ortho Biotech

Exhibitors
Dendreon Corporation
Endo Pharmaceuticals
Ferring Pharmaceuticals, Inc.
Galil Medical
GE Healthcare
IBA/WILEX
Mitomics, Inc.
Prometheus Labs
Watson Pharma, Inc.